Maravai LifeSciences Holdings, Inc. reported its Q3 2026 financial results, noting significant revenue dependency on CleanCap® for vaccine programs and ongoing risks from organizational changes and workforce reductions. As of October 29, 2026, the company had 149,254,467 Class A and 110,684,080 Class B shares outstanding, while maintaining its status as an accelerated filer.
Maravai LifeSciences reported Q3 2026 total revenue of $45.9 million, a 10% increase year-over-year, driven by strong demand for mRNA products and GMP consumables. The company narrowed its net loss to $24.0 million and raised its full-year 2026 revenue and Adjusted EBITDA guidance based on positive momentum in its TriLink and Cygnus segments.
Term
Q3 2026
“Our third- quarter results build on the momentum we established in the first half of the year. TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”
Bernd Brust, CEO of Maravai LifeSciences
“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”